Basma M. El-Khalifa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Basma M. El-Khalifa has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Bahaa Elfakharany
Radiation Therapy Department, Baheya Hospital, Giza, Egypt
3 shared publications - Eman Ayman Nada
Faculty of Pharmacy, Tanta University, Gharbia, Egypt
3 shared publications - Hazem M. Mazy
Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publications - Israa Ahmed Qutob
Faculty of Medicine, Alexandria University, Alexandria, Egypt
3 shared publications - Jamal Ahmad
Collage of Medicine and Health Sciences, Palestine Polytechnic University, Hebron, Palestine
3 shared publications - Abdelaziz A. Awad
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1) , 611
Analgesic efficacy of uni-level erector spinae plane block in breast cancer surgery patients: a systematic review and Meta-analysis
- 12 October 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1) , 611
Open AccessAnalgesic efficacy of uni-level erector spinae plane block in breast cancer surgery patients: a systematic review and Meta-analysis
- Open Access
- 22 August 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1) , 344
Erector spinae plane block (ESPB) versus paravertebral plane block (PVB) in managing post-operative pain in breast cancer patients: a systematic review and meta-analysis
- 22 August 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1) , 344
Open AccessErector spinae plane block (ESPB) versus paravertebral plane block (PVB) in managing post-operative pain in breast cancer patients: a systematic review and meta-analysis
- Open Access
- 27 March 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Efficacy of swab-based RUT in detecting H. pylori infection: a systematic review and meta-analysis
Introduction: Helicobacter pylori ( H. pylori ) is a gram-negative bacterium found in the gastric mucosa of humans. In this systematic review, our objective was to assess the diagnostic performance of the swab technique in detecting H. pylori infection. Methods: We followed the PRISMA guidelines and searched four databases for studies comparing the efficacy of swabs or sweeping techniques in detecting H. pylori infection. Outcomes were diagnostic accuracy measures, such as sensitivity and specificity. Results: Four studies with 658 patients were included. Compared to conventional diagnosis methods, overall sensitivity was 0.93, with a 95% CI (0.85; 0.97). A confusion matrix was used to summarize the previously mentioned results. Gastric swabs reported a high sensitivity of 93.7%, with a high number of true positives = 285. However, test specificity is moderate (74.1%). Conclusion: These results indicate that gastric swab-based RUT may be helpful as an initial diagnostic test, specifically if a biopsy is difficult. More studies with large sample sizes are needed to confirm these findings.
- 27 March 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessEfficacy of swab-based RUT in detecting H. pylori infection: a systematic review and meta-analysis
Introduction: Helicobacter pylori ( H. pylori ) is a gram-negative bacterium found in the gastric mucosa of humans. In this systematic review, our objective was to assess the diagnostic performance of the swab technique in detecting H. pylori infection. Methods: We followed the PRISMA guidelines and searched four databases for studies comparing the efficacy of swabs or sweeping techniques in detecting H. pylori infection. Outcomes were diagnostic accuracy measures, such as sensitivity and specificity. Results: Four studies with 658 patients were included. Compared to conventional diagnosis methods, overall sensitivity was 0.93, with a 95% CI (0.85; 0.97). A confusion matrix was used to summarize the previously mentioned results. Gastric swabs reported a high sensitivity of 93.7%, with a high number of true positives = 285. However, test specificity is moderate (74.1%). Conclusion: These results indicate that gastric swab-based RUT may be helpful as an initial diagnostic test, specifically if a biopsy is difficult. More studies with large sample sizes are needed to confirm these findings.
- 28 February 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 102
Efficacy and safety of delgocitinib in the treatment of chronic hand eczema: a systematic review and meta-analysis of randomized controlled trials
- 28 February 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 102
Efficacy and safety of delgocitinib in the treatment of chronic hand eczema: a systematic review and meta-analysis of randomized controlled trials
- Open Access
- 3 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 1-36
Propofol Versus Remimazolam in Gastrointestinal Endoscopy: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background Propofol is the most commonly used intravenous anesthetic for endoscopic surgery, although it comes with various adverse effects. Research indicates that Remimazolam, which is considered a safe general anesthetic, is being increasingly adopted as an alternative to propofol in clinical settings. Our meta-analysis sought to evaluate whether the rate of adverse reactions associated with Remimazolam in gastrointestinal endoscopic procedures is acceptable, and whether its surgical success rate is at least comparable to that of propofol. Methods Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched five electronic databases (PubMed, Scopus, Cochrane Library, Embase, and Web of Science) to identify eligible studies published up to January 2025. Using R version R.4.4, we reported outcomes as risk ratios (RRs) or mean differences (MDs) and confidence intervals (CIs). A P-value of ≤ 0.05 is considered statistically significant. Results Our meta-analysis included 37 studies encompassing 8533 patients. The results, analyzed using a random effects model, demonstrated no statistically significant difference in induction time between the two sedative groups, with an overall MD of 0.11 min (95% [- 0.10; 0.31], p = 0.2977). Patients in the Remimazolam group experienced longer total sedation times than those receiving Propofol, with an MD of 1.84 min (95% CI [0.61; 3.07], p = 0.0033). The pooled analysis indicated low heterogeneity (I2 = 4.2%). There was no statistically significant difference between the two sedatives in procedure time, with an MD of 0.16 (95% CI: [−0.13; 0.45], p = 0.2689). The pooled analysis displayed moderate heterogeneity (I2 = 43.5%, p = 0.0052). Conclusion Remimazolam has demonstrated safety, showing a reduced incidence of hypotension, bradycardia, respiratory depression, and hypoxemia compared to propofol. However, efficacy outcomes including the induction time and total procedure time were comparable between the two groups. However, the results were heterogeneous, which could be due to variability in the perfumed procedures, co-analgesics or dosing.
- 3 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 1-36
Open AccessPropofol Versus Remimazolam in Gastrointestinal Endoscopy: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background Propofol is the most commonly used intravenous anesthetic for endoscopic surgery, although it comes with various adverse effects. Research indicates that Remimazolam, which is considered a safe general anesthetic, is being increasingly adopted as an alternative to propofol in clinical settings. Our meta-analysis sought to evaluate whether the rate of adverse reactions associated with Remimazolam in gastrointestinal endoscopic procedures is acceptable, and whether its surgical success rate is at least comparable to that of propofol. Methods Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched five electronic databases (PubMed, Scopus, Cochrane Library, Embase, and Web of Science) to identify eligible studies published up to January 2025. Using R version R.4.4, we reported outcomes as risk ratios (RRs) or mean differences (MDs) and confidence intervals (CIs). A P-value of ≤ 0.05 is considered statistically significant. Results Our meta-analysis included 37 studies encompassing 8533 patients. The results, analyzed using a random effects model, demonstrated no statistically significant difference in induction time between the two sedative groups, with an overall MD of 0.11 min (95% [- 0.10; 0.31], p = 0.2977). Patients in the Remimazolam group experienced longer total sedation times than those receiving Propofol, with an MD of 1.84 min (95% CI [0.61; 3.07], p = 0.0033). The pooled analysis indicated low heterogeneity (I2 = 4.2%). There was no statistically significant difference between the two sedatives in procedure time, with an MD of 0.16 (95% CI: [−0.13; 0.45], p = 0.2689). The pooled analysis displayed moderate heterogeneity (I2 = 43.5%, p = 0.0052). Conclusion Remimazolam has demonstrated safety, showing a reduced incidence of hypotension, bradycardia, respiratory depression, and hypoxemia compared to propofol. However, efficacy outcomes including the induction time and total procedure time were comparable between the two groups. However, the results were heterogeneous, which could be due to variability in the perfumed procedures, co-analgesics or dosing.
- Open Access
- 10 November 2025
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 26 (1) , 1-8
Crispr/Cas9 gene editing in transfusion-dependent β-thalassemia and sickle cell disease: a systematic review of non-randomized clinical trials
Background: β-Thalassemia and sickle cell disease are the most common hereditary β-hemoglobinopathies. The current available treatments for their severe cases include frequent blood transfusions, iron chelation therapy, and allogenic hematopoietic stem cell transplantation (HSCT). Clustered Regularly Interspaced Short Palindromic Repeats (Crispr), offer a potentially safe and effective cure for these patients. This systematic review aims to report on its value in treating transfusion-dependent β-thalassemia (TDT), and sickle cell disease. Methods: This systematic review was conducted according to the Preferred Reporting Items of Systematic Reviews and Meta-analyses (PRISMA). A comprehensive search was done across available databases (PubMed, Scopus, Web of Science), until October 2024. Clinical trials on transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) patients undergoing Crispr/Cas9 gene editing technology, were included in this systematic review. Relevant data was extracted and interpreted. Results: Four non-randomized single-arm clinical trials, reporting a total of 101 patients in the full-analysis population, with a mean age of 18.1 years, were included in this review. Positive results were observed where TDT patients achieved transfusion independence, and vaso-occlusive events were either reduced or absent in SCD patients, across the follow-up duration. Notably, positive fetal hemoglobin (HbF) was achieved, aiding in the chronic anemia correction. Grade ≥ 3 adverse events were reported in 87.1% of patients, most commonly febrile neutropenia. Conclusion: Crispr/Cas9 reported high efficacy, with transfusion-independence and reducing vaso-occlusive events. HbF levels were significantly raised correcting the associated chronic anemia and elevating quality of life. Unfortunately, the incidence of grade ≥ 3 adverse events was high in the treated population, raising concerns about the potential safety of this technology.
- 10 November 2025
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 26 (1) , 1-8
Open AccessCrispr/Cas9 gene editing in transfusion-dependent β-thalassemia and sickle cell disease: a systematic review of non-randomized clinical trials
Background: β-Thalassemia and sickle cell disease are the most common hereditary β-hemoglobinopathies. The current available treatments for their severe cases include frequent blood transfusions, iron chelation therapy, and allogenic hematopoietic stem cell transplantation (HSCT). Clustered Regularly Interspaced Short Palindromic Repeats (Crispr), offer a potentially safe and effective cure for these patients. This systematic review aims to report on its value in treating transfusion-dependent β-thalassemia (TDT), and sickle cell disease. Methods: This systematic review was conducted according to the Preferred Reporting Items of Systematic Reviews and Meta-analyses (PRISMA). A comprehensive search was done across available databases (PubMed, Scopus, Web of Science), until October 2024. Clinical trials on transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) patients undergoing Crispr/Cas9 gene editing technology, were included in this systematic review. Relevant data was extracted and interpreted. Results: Four non-randomized single-arm clinical trials, reporting a total of 101 patients in the full-analysis population, with a mean age of 18.1 years, were included in this review. Positive results were observed where TDT patients achieved transfusion independence, and vaso-occlusive events were either reduced or absent in SCD patients, across the follow-up duration. Notably, positive fetal hemoglobin (HbF) was achieved, aiding in the chronic anemia correction. Grade ≥ 3 adverse events were reported in 87.1% of patients, most commonly febrile neutropenia. Conclusion: Crispr/Cas9 reported high efficacy, with transfusion-independence and reducing vaso-occlusive events. HbF levels were significantly raised correcting the associated chronic anemia and elevating quality of life. Unfortunately, the incidence of grade ≥ 3 adverse events was high in the treated population, raising concerns about the potential safety of this technology.